 HIV
and AIDS
- Library of Slides and Posters |
|
|
Resistance
Implications of 96 Weeks of Treatment with Once-
(QD) or Twice- (BID) Daily Lopinavir/ritonavir
(LPV/r) with Tenofovir DF (TDF) and Emtricitabine
(FTC) in Antiretroviral (ARV)-naïve
Subjects Daniel E. Cohen, Martin S. King, Christian
T.
D Cohen and others. EACS 2009.
|
 |
Improved
Treatment Compliance with Once-Daily (QD) Compared
to Twice-Daily (BID) Lopinavir/ritonavir
(LPV/r) in HIV-1-Infected, Antiretroviral-Experienced
Subjects
M King and others. EACS 2009.
|
|
Impact
of Baseline Resistance on Virologic Outcome with
Once-Daily (QD) or Twice-Daily (BID) Lopinavir/ritonavir
(LPV/r) through 48 Weeks of Combination
Antiretroviral Therapy in Treatment-Experienced,
HIV-1-Infected Subjects
M King and others. EACS 2009.
|
|
Simplifi
ed Antiretroviral Therapy in Special Populations:
Clinical Outcomesn at Week 48 of Lopinavir/ritonavir
(LPV/r) Tablet Dosed Once Daily (QD)
or Twice Daily (BID), Administered with .2 Nucleoside
Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced
Subjects, Analyzed by Gender, Age, Race, Ethnicity,
and Hepatitis Co-infection Status (Study M06-802)
I Gaultier and others. EACS
2009. |
|
Pharmacokinetic
interaction study between TMC278,
an NNRTI, and the contraceptives norethindrone
plus ethinylestradiol
H
Crauwels and others. EACS 2009. |
|
Absence
of a teratogenic potential from a novel next-generation
NNRTI, TMC278
M Desmidt and others. EACS
2009. |
|
Absorption,
metabolism and excretion of TMC278,
an NNRTI, after a single oral dose of 150mg in healthy
male volunteers
S Lachau-Durand and others.
EACS 2009. |
|
TMC278
25mg qd has no effect on corrected QT interval in
a study in HIV-negative volunteers
S Vanveggel and others. EACS
2009. |
|
Pharmacokinetic
interaction between etravirine
and lopinavir/ritonavir in HIV-negative
volunteers
M Schöller-Gyüre
and others. EACS 2009. |
|
Etravirine
demonstrates a favourable safety and tolerability
profile versus placebo irrespective of hepatitis
co-infection: Week 96 analysis from the DUET trials
B Clotet and others. EACS
2009. |
|
Etravirine
demonstrates a favourable safety and tolerability
profile: pooled 96-week results from the Phase III
DUET trials
P Girard and others. EACS
2009. |
|
Safety
and pharmacokinetics of etravirine
in pregnant HIV-infected women
P Izurieta and others. EACS
2009. |
|
Comparative
regimen durability and discontinuation reasons among
3-class experienced patients
in a US clinical cohort
J Willig and others. EACS
2009. |
|
Cost-effectiveness
of current treatment options in treatment-resistant
HIV/AIDS patients in the German setting
L Annemans and others. EACS
2009. |
|
The
economic impact
of national particularities in the healthcare system
– calculation for hospital-related costs from
pooled DUET trials by German diagnosis-related groups
M Stoll and others. EACS 2009.
|
HIV
and AIDS Articles |
|
Traditional
Cardiovascular Risk Factors Strongly Predict Likelihood
of Myocardial Infarction
in People with HIV |
|
Boosted
Darunavir (Prezista)
Monotherapy Works Well as Maintenance Therapy, but
Not So Well As Initial Regimen |
|
Revised
European HIV Treatment Guidelines Emphasize
Management of Age-related Non-AIDS Conditions and
Coinfections |
|
ASSERT
Study Adds to Comparative Data on Abacavir
(Ziagen, Epzicom) versus Tenofovir (Viread, Truvada) |
|
Small
Study Shows Etravirine
(Intelence) Appears Safe during Pregnancy |
|
|
|
HIV/HCV
and HIV/HBV Coinfection Articles |
|
|
German
Study Sheds Further Light on Hepatitis
C Sexual Transmission among HIV Positive
Gay Men |
|
|
Revised
European HIV Treatment Guidelines Emphasize
Management of Age-related Non-AIDS Conditions and
Coinfections |
|
|
|
|
|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
AASLD
2009 Coverage - HIV and Hepatiits.com Coverage of
AASLD 2009 |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
AASLD
2009 Coverage - HIV and Hepatiits.com Coverage of
AASLD 2009 |
| |
 |
